Nadixa (Nadifloxacin)

Nadifloxacin, the active ingredient in Nadixa, is a fluoroquinolone antibiotic presented as a topical formulation for cutaneous application. It targets bacterial DNA replication and is used to treat acne vulgaris and other superficial skin bacterial infections, providing localized antimicrobial activity while minimizing systemic exposure.

GNH USA supplies Nadixa as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies, and clinics across global markets while adhering to stringent quality and regulatory standards and ensuring reliable supply chain management.

Nadixa is a topical fluoroquinolone indicated for bacterial skin conditions. - Acne vulgaris: reduces inflammatory lesions and bacterial colonisation on the skin. - Impetigo: eradicates Staphylococcus aureus and Streptococcus pyogenes causing superficial skin infection. - Folliculitis: clears infected hair follicles and alleviates associated redness and pus formation.

Topical application of Nadixa may be associated with local and, rarely, systemic adverse reactions.

Common Side Effects: - Burning sensation: transient feeling of heat at the application site. - Stinging or itching: mild discomfort shortly after dosing. - Redness (erythema): localized skin reddening. - Dryness or peeling: mild desquamation of the treated area. - Pruritus: itching of the skin. - Contact dermatitis: localized allergic skin reaction.

Serious or Rare Side Effects: - Severe allergic reaction: angioedema or anaphylaxis requiring immediate medical attention. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: extensive skin detachment. - Photosensitivity: heightened skin reaction to sunlight. - Systemic fluoroquinolone effects: tendonitis or tendon rupture (very rare with topical use). - Persistent ulceration or necrosis at the application site.

When using Nadixa, several precautions should be observed to ensure safety and efficacy. - Hypersensitivity: discontinue use if the patient shows signs of allergic reaction. - Extensive or broken skin: avoid application on large areas or open wounds to limit systemic absorption. - Concomitant topical antibiotics: do not combine with other topical antibacterial agents without professional guidance. - Phototoxic risk: advise patients to limit sun exposure and use sunscreen while treating the area. - Pediatric use: limit use in children unless specifically prescribed by a qualified clinician. - Store at room temperature: keep the product in its original container, protect from moisture and direct light.

Nadixa may interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Systemic fluoroquinolones: concurrent use may increase risk of tendon toxicity. - Photosensitizing agents (e.g., tetracyclines, retinoids): heightened risk of severe photosensitivity reactions. - Other topical fluoroquinolones: additive local toxicity.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may mask signs of infection or reduce antibacterial efficacy. - Anticoagulants (e.g., warfarin): rare systemic absorption could potentiate anticoagulant effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential for increased systemic fluoroquinolone levels if absorbed.